Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IPR Battles Could Become Easier For BioPharma Patent Owners

Executive Summary

En banc Federal Circuit says patent owners do not have to prove patentability of amended claims in inter partes review proceedings; judges issue five opinions in fractured decision.

You may also be interested in...



Patent Fees Increasing, Driven By Fewer Filings, Jump In PTAB Workload

US Patent and Trademark Office proposes 5% across the board patent fee adjustment plus targeted fee hikes; Patent Trial and Appeal Board costs have risen following Supreme Court's SAS Institute decision.

Court Gives Biopharma Patent Owners (A Little) Help In Inter Partes Review

In 9-4 en banc opinion, Federal Circuit finds PTAB decision that an inter partes review petition is not time-barred can be appealed; says Supreme Court left opening in Cuozzo ruling.

Congress Crafting Bill To Modify Patent Challenges In Wake Of Allergan-Mohawk Deal

House IP Subcommittee Chair Issa suggests legislation may address sovereign immunity and ways to make inter partes review process more palatable to patent owners.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel